London Cancer 

London Cancer is the integrated cancer system serving north east and central London and west Essex.

We work with healthcare providers in these areas to deliver comprehensive and seamless cancer care to all patients from diagnosis, through treatment, to living with and beyond cancer. We also work to promote awareness of the signs and symptoms of cancer and uptake of cancer screening programmes, with the aim of enabling earlier diagnosis and prevention where possible.

London Cancer transferred to the UCLH Cancer Collaborative in September 2016 and our work is one of the six pillars of the Collaborative.

Our 22 tumour pathway boards and expert reference groups are key to our work. Further information on each pathway board and ERG, including annual reports and meeting papers, can be found in the links on the left.

We are currently recruiting four clinical leaders to lead our tumour pathway boards and expert reference groups - for more information visit our cancer blog.

Information about some of our key projects can be found in the links below. Please contact for further information.

  • Prostate radiotherapy patient information films

    The North Central and East London Cancer Alliance are pleased to announce the release of our new prostate radiotherapy patient information films produced by and starring clinicians and patients from the network. The three information films aim to help patients understand what to expect before, during and after having prostate radiotherapy treatment.

    The links to the english language videos are below:

    • Before radiotherapy;
    • During radiotherapy;
    • After radiotherapy;

    The films have been translated into the four languages most commonly spoken by patients who attend hospitals in North East and Central London; Bulgarian, Bengali, Polish and Turkish.

  • Annual Reports 2018-19

    We are happy to publish our annual reports for this year which include our achievements from the last financial year and a preview of ambitions we have for the year to come. We would like to thank all our board members for their continued commitment and time, which have enabled us to accomplish so much.

    A link to each pathway board/expert reference group’s report is below:

  • Prostate cancer surgical school patient videos

    We have produced two new videos to help prepare patients from across north and east London and west Essex for prostate cancer surgery at University College London Hospitals NHS Foundation Trust.

    Surgical school opened its doors at UCLH in 2014 and has now seen over 1,500 patients. Patients with prostate cancer, who have been referred to UCLH as the specialist centre for the region, are invited to attend a one-off patient education workshop to help them prepare for their robotic prostatectomy. Run by specialist cancer and surgical nurses, the workshop provides a relaxed atmosphere for patients to learn more about their surgery, pre and post-operative care and advice on diet and exercise to aid recovery.

    A short (3 min) video explains why patients and their families should attend surgical school. A  longer video is aimed at people that have attended surgical school and would like a refresh on the content of the session, as well as those that cannot attend. Both videos can be viewed below and on the UCLH prostate cancer support webpage.

    Both videos have been translated into the five most requested languages to our prostate cancer team and these can be found by clicking on the links – Bengali, Bulgarian, Portuguese, Russian and Turkish.

    Promotional video (3 min)


    Refresher video (37 min)
  • Medicines optimisation

    Medicines optimisation is a key theme running throughout our new models of care programme. Recognising that the pharmaceutical industry would play a key role in any successful programme, we challenged organisations to submit proposals that would help us to deliver improvements in the use of cancer medicines.

    The challenge to industry – the Pharma Challenge – was issued with the support of the Association of British Pharmaceutical Industries (ABPI) and the Ethical Medicines Industry Group. Pharmaceutical companies were invited to submit proposals to improve the availability and delivery of cancer drugs which were judged by a panel of chief pharmacists, nurses, clinicians, health science and other professionals.

    One of these collaborations with the pharmaceutical company Amgen is led by UCLH Cancer Collaborative. The project is to map out and measure the most efficient out-of-hospital administration of denosumab (also known as Xgeva). Denosumab is a targeted therapy for the treatment of secondary breast cancer in the bone.

    Outputs from one-to-one stakeholder interviews, workshops and patient surveys have fed into a simulation modelling tool that allows different delivery scenarios, whether at hospital, in primary care, in the community or at home to be tested for financial and patient experience impact.

    This project has featured in a short film as part of the Royal Society of Medicine's 21st century programme. You can view the film below.

    The film features UCLH Cancer Collaborative director, Nick Kirby, and lead cancer pharmacist Pinkie Chambers, as well as Paola Domizio, a UCLH patient who is taking part in the pilot project.

    Related to this project is a pilot offering denosumab self-administration in the home. 12 patients have been enrolled onto the programme, with patient experience and associated learning captured. The results of this project, combined with the outcome of the simulation modelling, will help trusts within UCLH Cancer Collaborative understand how best to offer chemotherapy at home or in the community.

    For further information on Pharma Challenge visit the Cancer Vanguard website or contact

  • Patient information films - blood diseases

    We have produced a series of films to help patients, their families and carers learn more about some of the most common tests and procedures used to diagnose and treat blood diseases including; bone marrow test, lumbar puncture, lymph node biopsy, PICC insertion, PET CT scan and blood transfusion.

    Each film is available in English and also with subtitles in Arabic, Bengali, Chinese, Farsi, Polish, Portuguese, Somali, Spanish and Turkish.


  • Multi-disciplinary team (MDT) improvement project

    All patients with a cancer diagnosis are looked after by a specialist multidisciplinary team (MDT). MDTs bring together clinicians, nurses and other staff with the necessary knowledge, skills and experience to ensure high quality diagnosis, treatment and care. The MDT meets weekly and the aim of their meeting is to offer high quality diagnosis and expert patient-centred treatment recommendations.

    In 2016/17 we were set the task of reviewing multi-disciplinary team (MDT) effectiveness within the region to determine how a range of MDTs currently work, and make recommendations to improve their ways of working and effectiveness. The process started with a workshop in June 2016 which brought together a wide range of stakeholders to explore the key issues. We visited 13 MDTs and received input from 12 MDT leads and 36 coordinators focusing on issues including:

    • Inefficiencies
    • IT issues, including e-referrals
    • Role of the MDT chair
    • Examples of best practice
    • Stratification of pathways to reduce meeting times and ensure more time is spent discussing ‘complex’ cases.

    The conclusion of this work programme is the London Cancer MDT Improvement report which sets out 21 recommendations, based on our findings that suggest improvements to MDT working and efficiency. London Cancer will now be working closely with our partners to implement some of the improvements suggested in the report through the MDT QI workstream.

    Watch our video on improving the effectiveness of multidisciplinary teams.

    For more information about multidisciplinary team improvement, please contact

 Upcoming events